Conatus Pharmaceuticals (NASDAQ:CNAT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
According to Zacks, “Conatus is progressing well with its lead candidate, emricasan, currently being developed for treatment of NASH (nonalcoholic steatohepatitis). Any regulatory setback for the candidate could hamper the company’s prospects. Notably, several companies are working to introduce treatments for NASH, which might make the market competitive for emricasan. Moreover, the company has had its share of pipeline obstacles too. However, Conatus’ agreement with Novartis for emricasan is a big boost as it not only lends expertise to the company but also provides it with funds to develop emricasan. This apart, the company’s portfolio has IDN-7314, which is being studied for primary sclerosing cholangitis and also boasts great potential. Shares of the company have underperformed the industry in the past year.”
Several other equities analysts have also commented on the stock. ValuEngine raised shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 1st. Oppenheimer set a $14.00 price target on shares of Conatus Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 3rd. SunTrust Banks dropped their price target on shares of Conatus Pharmaceuticals to $4.30 and set a “buy” rating for the company in a research report on Thursday, April 5th. Finally, HC Wainwright dropped their price target on shares of Conatus Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Thursday, April 5th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $12.14.
Conatus Pharmaceuticals traded down $0.03, hitting $4.54, on Wednesday, Marketbeat reports. 184,449 shares of the company were exchanged, compared to its average volume of 831,689. Conatus Pharmaceuticals has a twelve month low of $3.22 and a twelve month high of $7.95. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.41 and a current ratio of 2.41. The firm has a market capitalization of $137.39 million, a price-to-earnings ratio of -7.44 and a beta of 1.29.
Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Wednesday, May 2nd. The biotechnology company reported ($0.17) EPS for the quarter, hitting the consensus estimate of ($0.17). Conatus Pharmaceuticals had a negative net margin of 49.30% and a negative return on equity of 64.30%. The firm had revenue of $9.74 million during the quarter, compared to analyst estimates of $8.88 million. equities analysts forecast that Conatus Pharmaceuticals will post -0.68 EPS for the current fiscal year.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in CNAT. BlackRock Inc. grew its stake in Conatus Pharmaceuticals by 45.4% during the first quarter. BlackRock Inc. now owns 2,316,808 shares of the biotechnology company’s stock worth $13,601,000 after buying an additional 723,413 shares during the period. MPM Asset Management LLC grew its stake in Conatus Pharmaceuticals by 17.3% during the first quarter. MPM Asset Management LLC now owns 2,464,807 shares of the biotechnology company’s stock worth $14,468,000 after buying an additional 363,636 shares during the period. American Century Companies Inc. purchased a new stake in Conatus Pharmaceuticals during the first quarter worth approximately $643,000. Geode Capital Management LLC grew its stake in Conatus Pharmaceuticals by 26.2% during the fourth quarter. Geode Capital Management LLC now owns 429,556 shares of the biotechnology company’s stock worth $1,983,000 after buying an additional 89,179 shares during the period. Finally, Macquarie Group Ltd. grew its stake in Conatus Pharmaceuticals by 116.8% during the fourth quarter. Macquarie Group Ltd. now owns 130,300 shares of the biotechnology company’s stock worth $602,000 after buying an additional 70,200 shares during the period. Institutional investors own 40.56% of the company’s stock.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.